These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12084498)

  • 1. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle.
    de Boer AH; Le Brun PP; van der Woude HG; Hagedoorn P; Heijerman HG; Frijlink HW
    Eur J Pharm Biopharm; 2002 Jul; 54(1):17-24. PubMed ID: 12084498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.
    Le Brun PP; de Boer AH; Mannes GP; de Fraîture DM; Brimicombe RW; Touw DJ; Vinks AA; Frijlink HW; Heijerman HG
    Eur J Pharm Biopharm; 2002 Jul; 54(1):25-32. PubMed ID: 12084499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
    de Boer AH; Hagedoorn P; Westerman EM; Le Brun PP; Heijerman HG; Frijlink HW
    Eur J Pharm Sci; 2006 Jun; 28(3):171-8. PubMed ID: 16650739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study.
    Westerman EM; de Boer AH; Le Brun PPH; Touw DJ; Frijlink HW; Heijerman HGM
    Int J Pharm; 2007 Apr; 335(1-2):41-45. PubMed ID: 17178200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dextran Microparticulate Inhalable Dry Powder for the Treatment of Cystic Fibrosis and Mucopolysaccharidosis.
    Solanki NR; Patel DH; Talele DR
    Curr Drug Deliv; 2020; 17(3):218-228. PubMed ID: 31969100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.
    Westerman EM; De Boer AH; Le Brun PP; Touw DJ; Roldaan AC; Frijlink HW; Heijerman HG
    J Cyst Fibros; 2007 Jul; 6(4):284-92. PubMed ID: 17185047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2003 Jul; 260(2):187-200. PubMed ID: 12842339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulization.
    Akkerman-Nijland AM; Grasmeijer F; Kerstjens HAM; Frijlink HW; van der Vaart H; Vonk JM; Hagedoorn P; Rottier BL; Koppelman GH; Akkerman OW
    PLoS One; 2020; 15(9):e0239658. PubMed ID: 32970760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols.
    de Boer AH; Gjaltema D; Hagedoorn P; Schaller M; Witt W; Frijlink HW
    Int J Pharm; 2002 Dec; 249(1-2):233-45. PubMed ID: 12433451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
    Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
    AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction.
    Kozáková J; Altay A; Ždímal V; Mašková L; Sonvico F; Quarta E; Rossi A; Buttini F; Colombo G
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1664-1673. PubMed ID: 31389270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.
    Westerman EM; Le Brun PP; Touw DJ; Frijlink HW; Heijerman HG
    J Cyst Fibros; 2004 Mar; 3(1):23-8. PubMed ID: 15463883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling.
    Ling J; Mangal S; Park H; Wang S; Cavallaro A; Zhou QT
    J Pharm Sci; 2019 Sep; 108(9):3146-3151. PubMed ID: 31112716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dry powder inhalers in cystic fibrosis].
    Steinkamp G
    Pneumologie; 2014 Jun; 68(6):378-85. PubMed ID: 24664997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
    Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
    Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.
    Mangal S; Xu R; Park H; Zemlyanov D; Shetty N; Lin YW; Morton D; Chan HK; Li J; Zhou QT
    Pharm Res; 2018 Nov; 36(1):6. PubMed ID: 30406281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.